227 related articles for article (PubMed ID: 17683483)
1. A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine.
Eyerman DJ; Yamamoto BK
J Neurochem; 2007 Nov; 103(3):1219-27. PubMed ID: 17683483
[TBL] [Abstract][Full Text] [Related]
2. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis.
Guillot TS; Shepherd KR; Richardson JR; Wang MZ; Li Y; Emson PC; Miller GW
J Neurochem; 2008 Sep; 106(5):2205-17. PubMed ID: 18643795
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of methamphetamine-induced toxicity in the rat striatum by unpredictable stress: contribution of enhanced hyperthermia.
Tata DA; Raudensky J; Yamamoto BK
Eur J Neurosci; 2007 Aug; 26(3):739-48. PubMed ID: 17686046
[TBL] [Abstract][Full Text] [Related]
4. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.
Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA
J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422
[TBL] [Abstract][Full Text] [Related]
5. Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
Horton DB; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Oct; 339(1):286-97. PubMed ID: 21778282
[TBL] [Abstract][Full Text] [Related]
6. The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity.
Thomas DM; Francescutti-Verbeem DM; Kuhn DM
J Neurochem; 2008 May; 105(3):605-16. PubMed ID: 18088364
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes.
Midde NM; Gomez AM; Zhu J
J Neuroimmune Pharmacol; 2012 Sep; 7(3):629-39. PubMed ID: 22570010
[TBL] [Abstract][Full Text] [Related]
8. Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.
Nickell JR; Krishnamurthy S; Norrholm S; Deaciuc G; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2010 Feb; 332(2):612-21. PubMed ID: 19855096
[TBL] [Abstract][Full Text] [Related]
9. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.
Lee NR; Zheng G; Leggas M; Janganati V; Nickell JR; Crooks PA; Bardo MT; Dwoskin LP
J Pharmacol Exp Ther; 2019 Nov; 371(2):526-543. PubMed ID: 31413138
[TBL] [Abstract][Full Text] [Related]
10. Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.
Chu PW; Hadlock GC; Vieira-Brock P; Stout K; Hanson GR; Fleckenstein AE
J Neurochem; 2010 Oct; 115(2):325-32. PubMed ID: 20649837
[TBL] [Abstract][Full Text] [Related]
11. Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors.
Xu W; Zhu JP; Angulo JA
Synapse; 2005 Nov; 58(2):110-21. PubMed ID: 16088948
[TBL] [Abstract][Full Text] [Related]
12. Bupropion increases striatal vesicular monoamine transport.
Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
[TBL] [Abstract][Full Text] [Related]
13. Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans.
Boileau I; Houle S; Rusjan PM; Furukawa Y; Wilkins D; Tong J; Selby P; Wilson AA; Kish SJ
Synapse; 2010 Jun; 64(6):417-20. PubMed ID: 20169578
[TBL] [Abstract][Full Text] [Related]
14. Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.
Lohr KM; Stout KA; Dunn AR; Wang M; Salahpour A; Guillot TS; Miller GW
ACS Chem Neurosci; 2015 May; 6(5):790-9. PubMed ID: 25746685
[TBL] [Abstract][Full Text] [Related]
15. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity.
Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE
Synapse; 2009 Feb; 63(2):147-51. PubMed ID: 19021208
[TBL] [Abstract][Full Text] [Related]
16. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum.
Eyerman DJ; Yamamoto BK
J Pharmacol Exp Ther; 2005 Jan; 312(1):160-9. PubMed ID: 15331654
[TBL] [Abstract][Full Text] [Related]
17. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
Hansen JP; Riddle EL; Sandoval V; Brown JM; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2002 Mar; 300(3):1093-100. PubMed ID: 11861820
[TBL] [Abstract][Full Text] [Related]
18. Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo.
Meyer AC; Neugebauer NM; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
J Neurochem; 2013 Oct; 127(2):187-98. PubMed ID: 23875705
[TBL] [Abstract][Full Text] [Related]
19. Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.
Hadlock GC; Chu PW; Walters ET; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2010 Oct; 335(1):207-12. PubMed ID: 20622144
[TBL] [Abstract][Full Text] [Related]
20. Environmental enrichment reduces methamphetamine cue-induced reinstatement but does not alter methamphetamine reward or VMAT2 function.
Hofford RS; Darna M; Wilmouth CE; Dwoskin LP; Bardo MT
Behav Brain Res; 2014 Aug; 270():151-8. PubMed ID: 24821405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
